Cargando…
Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation
The genomic inter-individual heterogeneity remains a significant challenge for both clinical decision-making and the design of clinical trials. Although next-generation sequencing (NGS) is increasingly implemented in drug development and clinical trials, translation of the obtained genomic informati...
Autores principales: | Lauschke, Volker M., Ingelman-Sundberg, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057970/ https://www.ncbi.nlm.nih.gov/pubmed/32194983 http://dx.doi.org/10.1038/s41525-020-0119-2 |
Ejemplares similares
-
Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2023) -
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
por: Lauschke, Volker M., et al.
Publicado: (2016) -
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
por: Lauschke, Volker M., et al.
Publicado: (2019) -
Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
por: Hiratsuka, Masahiro, et al.
Publicado: (2021) -
Integrating rare genetic variants into pharmacogenetic drug response predictions
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2018)